Deletion of CBFB in a patient with acute myelomonocytic leukemia (AML M4Eo) and inversion 16

Cancer Genetics and Cytogenetics

Volumn 154, Issue 1, 2004, Pages 60-62

  Egan, Nicole ^a   O'Reilly, John ^a   Chipper, Lucia ^a   Higgins, Melinda ^a   Herrmann, Richard ^a   Cannell, Paul ^a  

^a ROYAL PERTH HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE MYELOMONOCYTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER PATIENT; CASE REPORT; CHROMOSOME 16P; CHROMOSOME DELETION; CHROMOSOME INVERSION; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL;

ADOLESCENT; CHROMOSOMES, HUMAN, PAIR 16; CLONE CELLS; GENE DELETION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INVERSION, CHROMOSOME; LEUKEMIA, MYELOMONOCYTIC, ACUTE; MALE;

EID: 4644293481     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2004.01.022     Document Type: Article

References (13)

1. R.A. Larson, S.F. Williams, M.M. Le Beau, M.A. Bitter, J.W. Vardiman, and J.D. Rowley Acute myelomonocytic leukemia with abnormal eosinophils and inv(16) or t(16;16) has a favorable prognosis Blood 68 1986 1242 1249
2. D. Grimwade, H. Walker, F. Oliver, K. Wheatley, C. Harrison, G. Harrison, J. Rees, I. Hann, R. Stevens, A. Burnett, A. Goldstone, and Medical Research Council Adult and Children's Leukaemia Working Parties The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML10 trial Blood 92 1998 2322 2333
3. J.C. Byrd, K. Mrozek, R.K. Dodge, A.J. Carroll, C.G. Edwards, D.C. Arthur, M.J. Pettenati, S.R. Patil, K.W. Rao, M.S. Watson, P.R.K. Koduru, J.O. Moore, R.M. Stone, R.J. Mayer, E.J. Feldman, F.R. Davey, C.A. Schiffer, R.A. Larson, C.D. Bloomfield, and Cancer and Leukemia Group B (CALGB 8461) Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461) Blood 100 2002 4325 4336
4. F. Mitelman An international system for human cytogenetic nomenclature 1995 S. Karger Basel
5. Van Dongen J.J.M., E.A. MacIntyre, J.A. Gabert, E. Delabesse, V. Rossi, G. Saglio, E. Gottardi, A. Rambaldi, G. Dotti, F. Griesinger, A. Parreira, P. Gameiro, M. Gonzales Diaz, M. Malec, A.W. Langerak, J.F. San Miguel, and A. Biondi Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia Leukemia 13 1999 1901 1928
6. P. Marlton, M. Keating, H. Kantarjian, S. Pierce, S. O'Brien, E.J. Freireich, and E. Estey Cytogenetic and clinical correlations in AML patients with abnormalities of chromosome 16 Leukemia 9 1995 965 971
7. D.F. Claxton, P. Liu, H.B. Hsu, P. Marlton, J. Hester, F. Collins, A.B. Deisseroth, J.D. Rowley, and M.J. Siciliano Detection of fusion transcripts generated by the inversion 16 chromosome acute myelogenous leukemia Blood 83 1994 1750 1756
8. E. Kolomietz, J. Al-Maghrabi, S. Brennan, J. Karaskova, S. Minkin, J. Lipton, and J. Squire Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis Blood 97 2001 3581 3588
9. D. Martinet, D. Muhlematter, M. Leeman, V. Parlier, U. Hess, J. Gmur, and M. Jotterand Detection of 16p deletions by FISH in patients with inv(16) or t(16;16) in acute myeloid leukemia (AML) Leukemia 11 1997 964 970
10. P. Marlton, D.F. Claxton, P. Liu, E.H. Estey, M. Beran, M. LeBeau, J.R. Testa, F.S. Collins, J.D. Rowley, and M.J. Siciliano Molecular characterization of 16p deletions associated with inversion 16 defines the critical fusion for leukemogenesis Blood 85 1995 772 779
11. B.J.P. Huntly, A.G. Reid, A.J. Bench, L.J. Campbell, N. Telford, P. Shepherd, J. Szer, H.M. Prince, P. Turner, C. Grace, E.P. Nacheva, and A.R. Green Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia Blood 98 2001 1732 1738
12. N. Cohen, G. Rozenfeld-Granot, I. Hardan, F. Brok-Simoni, N. Amariglio, G. Rechavi, and L. Trakhtenbrot Subgroup of patients with Philadelphia-positive chronic myelogenous leukemia characterized by a deletion of 9q proximal to ABL gene: expression profiling, resistance to interferon therapy, and poor prognosis Cancer Genet Cytogenet 128 2001 114 119
13. C. Herens, F. Tassin, V. Lemaire, Y. Beguin, E. Collard, S. Lampertz, C. Croisiau, M. Lecomte, B. De Prijk, L. Longree, and L. Koulischer Deletion of the 5′-ABL region: a recurrent anomaly detected by fluorescence in situ hybridization in about 10% of Philadelphia-positive chronic myeloid leukaemia patients Br J Haematol 110 2000 214 216